The findings indicate that treatment with TNF-α inhibitors (i.e., adalimumab, etanercept, infliximab) reduced the risk of stroke and transient ischemic attack by almost 50%, compared to treatment with methotrexate (132). The gene discussed is TNF; the disease is Stroke.